张岩 研究员/长聘副教授

联系方式

zhangyan9876@pku.edu.cn

研究方向

主要从事心血管生理和病生理学研究，研究方向是心肌细胞损伤和保护机制。

个人简介

北京大学心血管研究所研究员/长聘副教授，血管稳态与重构全国重点实验室PI，北京大学博雅特聘教授，博士生导师。国家杰青，万人计划青年拔尖人才。于北京大学医学部获临床医学学士学位和生理学博士学位。主要从事心血管生理和病生理学研究，研究方向是心肌细胞损伤和保护机制。作为课题负责人获得国家自然科学基金5项，科技部国家重点研发计划子课题1项。发表论文54篇，其中第一作者/通讯作者27篇，包括Nature，Cell，Nature Medicine，Nature Cell Biology，和Circulation等。作为发明人获授权国家发明专利9项。现为中国生理学会理事，中国病理生理学会血管医学专业委员会委员、青年工作小组副主任，中国病理生理学会受体专业委员会青年委员，中国遗传学会衰老遗传学分会委员，中国老年学和老年医学学会老年病学分会常委，中国人体健康科技促进会血压防控与研究专业委员会副主任委员，海峡两岸医药卫生交流协老年医学专委会常委等。

学习经历/工作经历

教育情况：

2003/9 – 2008/7  北京大学医学部 生理学 博士  (导师：肖瑞平教授）

1998/9 – 2003/7  北京大学医学部 临床医学 学士

工作情况：

2020/10 – 至今  北京大学 医学部心血管研究所 研究员

2010/10 – 2020/9  北京大学 分子医学研究所  副研究员

2008/10 – 2010/9  北京大学 分子医学研究所  博士后

2005/10 – 2007/10 美国新泽西医科和牙科大学  博士后

科研成果（基金、论文等）

代表性论著：

1) Hu Q, Zhang J, Luo X, Hu P, Li J, Li F, Wang Z, Zhang S, Jiao Z, Liu Y, Duanmu J, Jin L, Xie P, Zhu W, Zheng W, Shang H, Hu X, Chen Z, Xiao RP, Zhang Y（张岩）*. Intracellular L-PGDS-derived 15d-PGJ2 inhibits CaMKII through lipoxidation to alleviate cardiac ischemia/reperfusion injury.  Circulation.  2025, 152, 41-57. (*独立通讯作者，影响因子38.6).

2) Zhang J^#, Zhao C^#, Zhang W^#, Zhang M^#, Li F, Shang H, Zheng W, Li Y, Quan L, Li X, Li H, Wang L, Zheng W, Zhou Yi, D W Wang*, Dong E*, Chen C*, Zhang Y（张岩）*. Danhong Injection targets CaMKII through Dihydrotanshinone I to alleviate cardiomyocyte death and inflammation in viral myocarditis.  Sci China Life Sci  .  2025, online first. (*共同通讯作者，影响因子9.5).

3) Zhang W^#, Zhang J^#, Wang Z^#, Li T^#, Liu C, Kang X, Cui X, Yang J, Qu H, Duanmu J, Peng Y, Wang K, Jin L, Xie P, Zheng W, Shang H, Liu Y, Tian Z, Liu Z, Jin Y, Li Y, Li N, Zhuo X, Wu Y, Shi X, Ma R, Sun Y, Zhang K, Fang X, Hu X*, Dong E*, Zhang S*, Zhang Y（张岩）^†. Extracellular RIPK3 Acts as a Danger-Associated Molecular Pattern to Exaggerate Cardiac Ischemia/Reperfusion Injury.  Circulation.  2024, 150, 1791-1811. (^†Senior author，影响因子38.6).

4) Wang WW^#, Ji SY^#, Zhang W^#, Zhang J^#, Cai C^#, Hu R^#, Zang SK, Miao L, Xu H, Chen LN, Yang Z, Guo J, Qin J, Shen DD, Liang P, Zhang Y（张岩）*, Zhang Y*. Structure-based design of non-hypertrophic apelin receptor modulator.  Cell  .  2024, 187, 1460-1475. (*共同通讯作者，影响因子42.5).

5) Lu S, Cao C, Zhang W, Li J, Yang J, Huang Z, Wu Z, Liu B, Huang H, Wang H, Wang Y, Liu D, Zhang Z, Liu K, Yang G, Gong X, Dai H, Li Y, Dong E*, Zhang X*, Zhang Y（张岩）*. Peficitinib suppresses diffuse-type tenosynovial giant cell tumor by targeting TYK2 and JAK/STAT signaling.  Sci China Life Sci  .  2025, 68, 593-609. (*共同通讯作者，影响因子9.5).

6) Wu Z^#, Shi Y^#, Cui Y, Xing X, Zhang L, Liu D, Zhang Y, Dong J, Jin L, Pang M, Xiao RP, Zhu Z, Xiong JW, Tong X, Zhang Y（张岩）*, Wang S*, Tang F*, Zhang B*. Single-cell analysis reveals an Angpt4-initiated EPDC-EC-CM cellular coordination cascade during heart regeneration.  Protein   Cell  .  2023, 14, 350-368. (*共同通讯作者，影响因子12.8).

7) Dong H^#, Zhang Y（张岩）^#, Sun D, Wang G, Zhang Q, Hidru TH, Yang Y, Wang S, Wei Y, Liu F, Zhang J, Xia Y*, Yang X*. Refining prediction of stroke in sinus node dysfunction patients without atrial fibrillation using a P-combined score: a multi-centre study.  Eur J Prev Cardiol.  2023, 21， 507-518. (*共同第一作者，影响因子7.5).

8) Zhang J, Liang R, Wang K, Zhang W, Zhang M, Jin L, Xie P, Zheng W, Shang H, Hu Q, Li J, Chen G, Wu F, Lan F, Wang L, Wang S.Q., Li Y, Zhang Y, Liu J, Lv F, Hu X, Xiao R.P., Lei X*, Zhang Y（张岩）*. Novel CaMKII-δ inhibitor hesperadin exerts dual functions to ameliorate cardiac ischemia/reperfusion injury and inhibit tumor growth.  Circulation . 2022, 145, 1154-1168. (*共同通讯作者，影响因子38.6).

9) Yao Y^#, Li F^#, Zhang M^#, Jin L, Xie P, Liu D, Zhang J, Hu X, Lv F, Shang H, Zheng W, Sun X, Duanmu J, Wu F, Lan F, Xiao RP., Zhang Y（张岩）*. Targeting CaMKII-δ9 Ameliorates Cardiac Ischemia/reperfusion Injury by Inhibiting Myocardial Inflammation.  Circ   Res . 2022, 130, 887-903. (*独立通讯作者，影响因子16.2).

10) Feng H^#, Shen H^#, Robeson MJ, Wu YH, Wu HK., Chen GJ, Zhang S, Xie P, Jin L, He Y, Wang Y, Lv F, Hu X, Zhang Y（张岩）*, Xiao RP. *. MG53 E3 ligase-dead mutant protects diabetic hearts from acute ischemic/reperfusion injury and ameliorates diet-induced cardiometabolic damage.  Diabetes.  2022, 71, 298-314. (*共同通讯作者，影响因子7.5).

11) Song Y, Xu C, Liu J, Li Y, Wang H, Shan D, Wainer I, Hu X, Zhang Y（张岩）*, Woo YH*, Xiao RP. Heterodimerization with 5-HT2BR is indispensable for b2AR-mediated cardioprotection.  Circ Res . 2021, 128, 262-277 (*共同通讯作者，影响因子16.2).

12) Shan D^#, Guo S^#, Wu HK, Lv F, Jin L, Zhang M, Xie P, Wang Y, Song Y, Wu F, Lan F, Hu X, Cao CM*, Zhang Y（张岩）*, Xiao RP*. Cardiac ischemic preconditioning promotes MG53 secretion through H₂O₂-activated PKC-d signaling.  Circulation . 2020, 142, 1077-1091 (*共同通讯作者，影响因子38.6).

13) Zhang M, Gao H, Liu D, Zhong X, Shi X, Yu P, Jin L, Liu Y, Tang Y, Song Y, Liu J, Hu X, Li CY, Song L, Qin J, Wu F, Lan F, Zhang Y（张岩）*, Xiao RP. CaMKII-d9 promotes cardiomyopathy through disrupting UBE2T-dependent DNA repair.  Nat Cell Biol . 2019, 21, 1152-1163 (*独立通讯作者，影响因子19.1).

14) Wu HK^#, Zhang Y（张岩）^#, Cao CM^#, Hu X, Fang M, Yao Y, Jin L, Chen G, Jiang P, Zhang S, Song R, Peng W, Liu F, Guo J, Tang L, He Y, Shan D, Huang J, Zhou Z, Wang D, Lv F*, Xiao RP*. Glucose-sensitive myokine/cardiokine MG53 regulates systemic insulin response and metabolic homeostasis.  Circulation . 2019, 139, 901-914 (^#共同第一作者，影响因子38.6).

15) Wang Y, Jin L, Song Y, Zhang M, Shan D, Liu Y, Lv F, Xiao RP, Zhang Y（张岩）*. β-arrestin 2 mediates cardiac ischemia-reperfusion injury via inhibiting GPCR-independent cell survival signaling.  Cardiovasc Res  .  2017, 113, 1615-1626 (*独立通讯作者，影响因子13.3).

16) Zhang T^#, Zhang Y（张岩）^#*, Cui M, Jin L, Wang Y, Lv F, Liu Y, Zheng W, Shang H, Zhang J, Zhang M, Wu HK, Guo J, Zhang X, Hu X, Cao CM, Xiao RP*. CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis.  Nat Med.  2016, 22, 175-182 (*共同通讯作者，^#共同第一作者，影响因子50.0).

17) Zhu W^#, Tsang S^#, Browe, DM^#, Woo AY, Huang Y, Xu C, Liu JF, Lv F, Zhang Y（张岩）*, Xiao RP*. Interaction of β1-adrenoceptor with RAGE mediates cardiomyopathy via CaMKII signaling.  JCI Insight. 2016, 1, e84969 (*共同通讯作者，影响因子6.1).

18) Song RS^#, Peng W^#, Zhang Y（张岩）^#, Lv F, Wu HK, Guo J, Cao Y, Pi Y, Zhang X, Jin L, Zhang M, Jiang P, Liu F, Meng S, Zhang X, Jiang P, Cao CM*, Xiao RP*. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders.  Nature. 2013, 494, 375-379 (^#共同第一作者，影响因子48.5).

19) Zhang Y（张岩）^#, Lv F^#, Jin L, Peng W, Song RS, Ma J, Cao CM*, Xiao RP*. MG53 participates in ischaemic postconditioning through the RISK signaling pathway.  Cardiovasc Res . 2011, 91, 108-115 (^#共同第一作者，影响因子13.3).

20) Cao CM^#, Zhang Y（张岩）^#, Weisleder N^#, Ferrante C, Wang X, Lv F, Zhang Y, Song R, Hwang M, Jin L, Guo J, Peng W, Li G, Nishi M, Takeshima H, Ma J*, Xiao RP*. MG53 constitutes a primary determinant of cardiac ischemic preconditioning.  Circulation . 2010, 121, 2565-2574 (^#共同第一作者，影响因子38.6).

21) Peng W^#, Zhang Y（张岩）^#, Zheng M, Cheng H, Zhu W, Cao CM*, Xiao RP*. Cardioprotection by CaMKII-δB is mediated by phosphorylation of HSF1 and subsequent expression of inducible HSP70.  Circ Res . 2010, 106, 102-110 (^#共同第一作者，影响因子16.2).